Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certification & Accreditation
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Ixekizumab and ustekinumab in psoriasis: post-hoc comparison of onset and duration of treatment response
By
- AMS
posted
Jun 26, 2020 10:08 AM
0
Recommend
.
0 comments
0 views
Related Content
Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics
- AMS
Added Aug 05, 2020
Blog Entry
New evidence-based resources to guide treatment of plaque psoriasis
- AMS
Added Sep 08, 2021
Blog Entry
Disease response and patient-reported outcomes among initiators of ixekizumab
- AMS
Added Dec 03, 2020
Blog Entry
American Society of Plastic Surgeons Unveils COVID-19’s Impact and Pent-Up Patient Demand Fueling the Industry's Current Post-Pandemic Boom
- AMS
Added May 18, 2021
Blog Entry
Researchers Analyze How Breast Implant Surfaces Influence Immune Response
- AMS
Added Jul 13, 2021
Blog Entry
Permalink
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic